HSIC

Business Context and Reporting Period

Company: Henry Schein, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 28, 2002 (52 weeks)
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. The company operates through two segments: Healthcare Distribution (dental, medical, veterinary, and international) and Technology (practice management software and value-added services). It serves over 400,000 customers worldwide.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10.4% to $2.825 billion, driven by a 10.2% increase in the Healthcare Distribution segment and an 18.7% increase in the Technology segment.
• Profitability: Operating income rose 33.3% to $197.0 million. Net income increased 35.0% to $118.0 million. Gross margin expanded 0.8 percentage points to 28.1%.
• Segment Performance:
  • Medical: Sales grew 11.3% due to increased sales to core physician offices and alternate care markets.
  • Dental: Sales grew 9.4%, driven by equipment sales and the "Privileges" loyalty program.
  • Technology: Sales grew 18.7%, aided by a new marketing initiative ("MarketOne") selling directly to end-users.
• Accounting Changes: The company adopted FAS 142, ceasing goodwill amortization. This resulted in a $7.3 million increase in net income for 2001 on a comparable basis and eliminated amortization expense in 2002.
• Restructuring & M&A: The company recorded a net credit of $1.2 million related to revised estimates of prior-year merger and integration costs. Restructuring costs were minimal ($0.4 million) compared to $14.4 million in 2000.

Guidance, Outlook, and Risks

• Capital Allocation: The Board authorized a $200 million share repurchase program (approx. 4.5% of outstanding shares). The company does not anticipate paying cash dividends.
• Liquidity: The company maintains a $200 million revolving credit facility (unused as of year-end) and $200.7 million in cash equivalents. Management believes liquidity is sufficient for foreseeable needs.
• Outlook: Management expects continued investment in capital projects (over $35 million) to modernize facilities and IT systems. Growth strategies focus on increasing share of wallet with existing customers, expanding the customer base, and strategic acquisitions.
• Risks:
  • Competition: Highly competitive industry with pressure from manufacturers selling directly and consolidation among distributors.
  • Regulatory: Subject to FDA, Prescription Drug Marketing Act, and Controlled Substances Act regulations.
  • Legal: Pending product liability claims (approx. 57 cases, including 47 regarding latex gloves) and a class action lawsuit regarding practice management software (decertified by Texas Supreme Court, but rehearing pending).
  • Market Risks: Exposure to foreign currency fluctuations and interest rate changes, though hedging programs are in place.

Investor Verification Checklist

• Goodwill Impairment: Verify the assumptions used in the annual goodwill impairment test under FAS 142, given the $310.3 million goodwill balance.
• Legal Contingencies: Monitor the status of the Texas Supreme Court rehearing regarding the software class action and the outcome of latex glove liability claims.
• Working Capital Trends: Review the increase in inventory ($23.1 million) and accounts receivable days sales outstanding (improved to 48.2 days) to ensure efficient capital management.
• Stock Repurchase Execution: Track the pace and pricing of the newly authorized $200 million share buyback program.
• Technology Segment Margins: Assess the sustainability of the Technology segment's high gross margin (76.5%) following the shift to direct sales via the MarketOne initiative.